1. Home
  2. NUVL vs AGCO Comparison

NUVL vs AGCO Comparison

Compare NUVL & AGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.60

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo AGCO Corporation

AGCO

AGCO Corporation

HOLD

Current Price

$116.92

Market Cap

8.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
AGCO
Founded
2017
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
8.2B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
NUVL
AGCO
Price
$123.60
$116.92
Analyst Decision
Strong Buy
Hold
Analyst Count
16
11
Target Price
$134.75
$119.09
AVG Volume (30 Days)
4.2M
668.7K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
1.05%
EPS Growth
N/A
271.35
EPS
N/A
0.76
Revenue
N/A
$10,082,000,000.00
Revenue This Year
N/A
$6.52
Revenue Next Year
$1,239.49
$5.56
P/E Ratio
N/A
$157.46
Revenue Growth
N/A
N/A
52 Week Low
$71.14
$99.21
52 Week High
$123.69
$143.78

Technical Indicators

Market Signals
Indicator
NUVL
AGCO
Relative Strength Index (RSI) 66.56 52.79
Support Level $98.56 $108.99
Resistance Level $123.62 $121.03
Average True Range (ATR) 0.21 3.47
MACD -0.05 0.72
Stochastic Oscillator 82.41 69.11

Price Performance

Historical Comparison
NUVL
AGCO

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About AGCO AGCO Corporation

Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealers and distribution locations and reaches into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its partnership with Rabobank of the Netherlands, having exited their JV in 2026.

Share on Social Networks: